Corrigendum to “Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer” [Clinical Lung Cancer 26 (2025) 573-582]
Clinical Lung Cancer · 2026-11 · 27 (9) · 51
DOI: 10.1016/j.cllc.2026.09.008 ↗Kurz gefasst
Korrektur in der Zeitschrift Clinical Lung Cancer, 2026-11. Verfasst von Weibo Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China.
- Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China. Electronic address: yanxiaolong@fmmu.edu.cn.
- Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China. Electronic address: drliuhg@163.com.
Zitieren
APA
Cao, W., Duan, H., Shao, C., Yan, X., & Liu, H. (2026). Corrigendum to “Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer” [Clinical Lung Cancer 26 (2025) 573-582]. Clinical Lung Cancer, 27(9), 51. https://doi.org/10.1016/j.cllc.2026.09.008
Vancouver
Cao W, Duan H, Shao C, Yan X, Liu H. Corrigendum to “Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer” [Clinical Lung Cancer 26 (2025) 573-582]. Clinical Lung Cancer. 2026;27(9):51. doi:10.1016/j.cllc.2026.09.008
BibTeX
@article{Cao2026,
author = {Cao, Weibo and Duan, Hongtao and Shao, Changjian and Yan, Xiaolong and Liu, Honggang},
title = {Corrigendum to “Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer” [Clinical Lung Cancer 26 (2025) 573-582]},
journal = {Clinical Lung Cancer},
year = {2026},
volume = {27},
number = {9},
pages = {51},
doi = {10.1016/j.cllc.2026.09.008}
}
EUVIMED